Equities

Diaceutics PLC

Diaceutics PLC

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Diaceutics PLC is a United Kingdom-based technology and solutions provider to pharma and biotech companies. It is engaged in research and development activities in the area of drug development science, precision medicine data and platform software. It provides pharma and biotech companies with an end-to-end commercialization solution for precision medicine through data analytics, scientific and advisory services enabled by its platform DXRX - The Diagnostics Network. It has two separate products and service lines: Insight & Engagement Solutions and Scientific & Advisory Services. Insight & Engagement Solutions includes access to the DXRX platform diagnostic testing data repository to utilize licensed data insight products, such as lab segmentation, physician segmentation, testing rate tracker and physician signal. Scientific Advisory Services comprise a range of services developed to help improve patient care by accelerating the development, delivery and uptake of precision medicine.

  • Revenue in GBP (TTM)26.10m
  • Net income in GBP-2.85m
  • Incorporated2005
  • Employees184.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.